Iconovo
Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines. By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.
Last updated on
About Iconovo
Founded
2013Estimated Revenue
$1M-$10MEmployees
11-50Funding / Mkt. Cap
$4MCategory
Sector
Health CareIndustry Group
Pharmaceuticals, Biotechnology & Life SciencesIndustry
PharmaceuticalsSIC Code
28NAICs Code
32541Location
City
LundState
SkaneCountry
SwedenIconovo
Find your buyer within Iconovo